Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2018, Article ID 5812802, 12 pages
https://doi.org/10.1155/2018/5812802
Research Article

A Novel Polymorphism in the Promoter of the CYP4A11 Gene Is Associated with Susceptibility to Coronary Artery Disease

1Department of Biology, Medical Genetics and Ecology, Kursk State Medical University, Karl Marx Street 3, Kursk 305041, Russia
2Department of Internal Medicine, Kursk State Medical University, 14 Pirogova St., Kursk 305035, Russia
3Laboratory of Genomic Research, Research Institute for Genetic and Molecular Epidemiology, Kursk State Medical University, Yamskaya Street 18, Kursk 305041, Russia
4Evolutionary Genetics Laboratory, Research Institute of Medical Genetics, Tomsk National Research Medical Center, 10 Nabereznaya Ushaiki, Tomsk 634050, Russia
5Department of Medical Biological Disciplines, Belgorod State University, 85 Pobeda St., Belgorod 308015, Russia
6Laboratory of Statistical Genetics and Bioinformatics, Research Institute for Genetic and Molecular Epidemiology, Kursk State Medical University, 18 Yamskaya St., Kursk 305041, Russia

Correspondence should be addressed to Alexey Polonikov; ur.relbmar@vokinolop

Received 11 September 2017; Revised 23 October 2017; Accepted 29 November 2017; Published 1 February 2018

Academic Editor: Agata M. Bielecka-Dabrowa

Copyright © 2018 Svetlana Sirotina et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. C. Notzon, Y. M. Komarov, S. P. Ermakov, C. T. Sempos, J. S. Marks, and E. V. Sempos, “Causes of declining life expectancy in Russia,” JAMA, vol. 279, no. 10, pp. 793–800, 1998. View at Publisher · View at Google Scholar · View at Scopus
  2. V. L. Roger, A. S. Go, D. M. Lloyd-Jones et al., “Heart disease and stroke statistics--2012 update: a report from the American Heart Association,” Circulation, vol. 125, no. 1, pp. e2–e220, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. N. Poulter, “Coronary heart disease is a multifactorial disease,” American Journal of Hypertension, vol. 12, no. S6, pp. 92S–95S, 1999. View at Publisher · View at Google Scholar
  4. D. K. Arnett, A. E. Baird, R. A. Barkley et al., “Relevance of genetics and genomics for prevention and treatment of cardiovascular disease: a scientific statement from the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group,” Circulation, vol. 115, no. 22, pp. 2878–2901, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. CARDIoGRAMplusC4D Consortium, P. Deloukas, S. Kanoni et al., “Large-scale association analysis identifies new risk loci for coronary artery disease,” Nature Genetics, vol. 45, no. 1, pp. 25–33, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Nikpay, A. Goel, H. H. Won et al., “A comprehensive 1,000 genomes-based genome-wide association meta-analysis of coronary artery disease,” Nature Genetics, vol. 47, no. 10, pp. 1121–1130, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. I. Fleming, “Cytochrome p450 and vascular homeostasis,” Circulation Research, vol. 89, no. 9, pp. 753–762, 2001. View at Publisher · View at Google Scholar
  8. B. N. Zordoky and A. O. El-Kadi, “Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases,” Pharmacology & Therapeutics, vol. 125, no. 3, pp. 446–463, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. R. N. Schuck, K. N. Theken, M. L. Edin et al., “Cytochrome P450-derived eicosanoids and vascular dysfunction in coronary artery disease patients,” Atherosclerosis, vol. 227, no. 2, pp. 442–448, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Waldman, S. J. Peterson, M. Arad, and E. Hochhauser, “The role of 20-HETE in cardiovascular diseases and its risk factors,” Prostaglandins & Other Lipid Mediators, vol. 125, pp. 108–117, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. F. A. Fitzpatrick and R. C. Murphy, “Cytochrome P-450 metabolism of arachidonic acid: formation and biological actions of "epoxygenase"-derived eicosanoids,” Pharmacological Reviews, vol. 40, no. 4, pp. 229–241, 1988. View at Google Scholar
  12. R. J. Roman, “P-450 metabolites of arachidonic acid in the control of cardiovascular function,” Physiological Reviews, vol. 82, no. 1, pp. 131–185, 2002. View at Publisher · View at Google Scholar
  13. M. Spiecker and J. K. Liao, “Vascular protective effects of cytochrome P450 epoxygenase derived eicosanoids,” Archives of Biochemistry and Biophysics, vol. 433, no. 2, pp. 413–420, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. A. A. Spector and H. Y. Kim, “Cytochrome P450 epoxygenase pathway of polyunsaturated fatty acid metabolism,” Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, vol. 1851, no. 4, pp. 356–365, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. W. CC, T. Gupta, V. Garcia, Y. Ding, and M. L. Schwartzman, “20-HETE and blood pressure regulation: clinical implications,” Cardiology in Review, vol. 22, no. 1, pp. 1–12, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. J. M. Lasker, W. B. Chen, I. Wolf, B. P. Bloswick, P. D. Wilson, and P. K. Powell, “Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of CYP4F2 and CYP4A11,” The Journal of Biological Chemistry, vol. 275, no. 6, pp. 4118–4126, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. J. V. Gainer, A. Bellamine, E. P. Dawson et al., “Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension,” Circulation, vol. 111, no. 1, pp. 63–69, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Liu, H. H. Jiang, D. K. Wu et al., “Effect of gene polymorphims on the warfarin treatment at initial stage,” The Pharmacogenomics Journal, vol. 17, no. 1, pp. 47–52, 2017. View at Publisher · View at Google Scholar · View at Scopus
  19. Z. Fu, T. Nakayama, N. Sato et al., “Haplotype-based case-control study of the human CYP4F2 gene and essential hypertension in Japanese subjects,” Hypertension Research, vol. 31, no. 9, pp. 1719–1726, 2008. View at Publisher · View at Google Scholar
  20. N. C. Ward, I. J. Tsai, A. Barden et al., “A single nucleotide polymorphism in the CYP4F2 but not CYP4A11 gene is associated with increased 20-HETE excretion and blood pressure,” Hypertension, vol. 51, no. 5, pp. 1393–1398, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Liu, Y. Zhao, D. Nie et al., “Association of a functional cytochrome P450 4F2 haplotype with urinary 20-HETE and hypertension,” Journal of the American Society of Nephrology, vol. 19, no. 4, pp. 714–721, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. Z. Fu, T. Nakayama, N. Sato et al., “A haplotype of the CYP4F2 gene associated with myocardial infarction in Japanese men,” Molecular Genetics and Metabolism, vol. 96, no. 3, pp. 145–147, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. Z. Fu, T. Nakayama, N. Sato et al., “Haplotype-based case-control study of CYP4A11 gene and myocardial infarction,” Hereditas, vol. 149, no. 3, pp. 91–98, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. Z. Fu, Y. Ma, X. Xie et al., “A novel polymorphism of the CYP4A11 gene is associated with coronary artery disease,” Clinical and Applied Thrombosis/Hemostasis, vol. 19, no. 1, pp. 60–65, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. J. S. Williams, P. N. Hopkins, X. Jeunemaitre, and N. J. Brown, “CYP4A11 T8590C polymorphism, salt-sensitive hypertension, and renal blood flow,” Journal of Hypertension, vol. 29, no. 10, pp. 1913–1918, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. B. Mayer, W. Lieb, A. Götz et al., “Association of the T8590C polymorphism of CYP4A11 with hypertension in the MONICA Augsburg echocardiographic substudy,” Hypertension, vol. 46, no. 4, pp. 766–771, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Polonikov, E. Vialykh, O. Vasil'eva et al., “Genetic variation in glutathione S-transferase genes and risk of nonfatal cerebral stroke in patients suffering from essential hypertension,” Journal of Molecular Neuroscience, vol. 47, no. 3, pp. 511–513, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. A. V. Polonikov, D. V. Ushachev, V. P. Ivanov et al., “Altered erythrocyte membrane protein composition mirrors pleiotropic effects of hypertension susceptibility genes and disease pathogenesis,” Journal of Hypertension, vol. 33, no. 11, pp. 2265–2277, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. A. V. Polonikov, O. Y. Bushueva, I. V. Bulgakova et al., “A comprehensive contribution of genes for aryl hydrocarbon receptor signaling pathway to hypertension susceptibility,” Pharmacogenetics and Genomics, vol. 27, no. 2, pp. 57–69, 2017. View at Publisher · View at Google Scholar · View at Scopus
  30. Z. Xu and J. A. Taylor, “SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies,” Nucleic Acids Research, vol. 37, Supplement 2, pp. W600–W605, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. J. R. González, L. Armengol, X. Solé et al., “SNPassoc: an R package to perform whole genome association studies,” Bioinformatics, vol. 23, no. 5, pp. 654-655, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. X. Solé, E. Guinó, J. Valls, R. Iniesta, and V. Moreno, “SNPStats: a web tool for the analysis of association studies,” Bioinformatics, vol. 22, no. 15, pp. 1928-1929, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. Y. Benjamini and Y. Hochberg, “Controlling the false discovery rate: a practical and powerful approach to multiple testing,” Journal of the Royal Statistical Society, vol. 57, pp. 289–300, 1995. View at Google Scholar
  34. N. L. Smith, L. A. Hindorff, S. R. Heckbert et al., “Association of genetic variations with nonfatal venous thrombosis in postmenopausal women,” JAMA, vol. 297, no. 5, pp. 489–498, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. L. Guo, Y. Du, S. Chang, K. Zhang, and J. Wang, “rSNPBase: a database for curated regulatory SNPs,” Nucleic Acids Research, vol. 42, no. D1, pp. D1033–D1039, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. B. Mayer, W. Lieb, A. Götz et al., “Association of a functional polymorphism in the CYP4A11 gene with systolic blood pressure in survivors of myocardial infarction,” Journal of Hypertension, vol. 24, no. 10, pp. 1965–1970, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Hermann, J. P. Hellermann, K. Quitzau et al., “CYP4A11 polymorphism correlates with coronary endothelial dysfunction in patients with coronary artery disease-the ENCORE trials,” Atherosclerosis, vol. 207, no. 2, pp. 476–479, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. R. Zhang, J. Lu, C. Hu et al., “A common polymorphism of CYP4A11 is associated with blood pressure in a Chinese population,” Hypertension Research, vol. 34, no. 5, pp. 645–648, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. Z. Fu, H. Yang, Y. Ma et al., “Haplotype study of the CYP4A11 gene and coronary artery disease in Han and Uygur populations in China,” Gene, vol. 512, no. 2, pp. 510–516, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. K. Sugimoto, H. Akasaka, T. Katsuya et al., “A polymorphism regulates CYP4A11 transcriptional activity and is associated with hypertension in a Japanese population,” Hypertension, vol. 52, no. 6, pp. 1142–1148, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Akira, H. Isshiki, T. Sugita et al., “A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family,” The EMBO Journal, vol. 9, no. 6, pp. 1897–1906, 1990. View at Google Scholar
  42. V. Poli, “The role of C/EBP isoforms in the control of inflammatory and native immunity functions,” The Journal of Biological Chemistry, vol. 273, no. 45, pp. 29279–29282, 1998. View at Publisher · View at Google Scholar · View at Scopus
  43. L. A. Cowart, S. Wei, M. H. Hsu et al., “The CYP4A isoforms hydroxylate epoxyeicosatrienoic acids to form high affinity peroxisome proliferator-activated receptor ligands,” The Journal of Biological Chemistry, vol. 277, no. 38, pp. 35105–35112, 2002. View at Publisher · View at Google Scholar · View at Scopus
  44. P. Gervois, I. P. Torra, J. C. Fruchart, and B. Staels, “Regulation of lipid and lipoprotein metabolism by PPAR activators,” Clinical Chemistry and Laboratory Medicine, vol. 38, no. 1, pp. 3–11, 2000. View at Publisher · View at Google Scholar
  45. S. A. Kliewer, S. S. Sundseth, S. A. Jones et al., “Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 9, pp. 4318–4323, 1997. View at Publisher · View at Google Scholar · View at Scopus
  46. S. E. Nissen, S. J. Nicholls, K. Wolski et al., “Effects of a potent and selective PPAR-α agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials,” JAMA, vol. 297, no. 12, pp. 1362–1373, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. S. Cuzzocrea, E. Mazzon, R. Di Paola et al., “The role of the peroxisome proliferator-activated receptor-α (PPAR-α) in the regulation of acute inflammation,” Journal of Leukocyte Biology, vol. 79, no. 5, pp. 999–1010, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. E. Hill, F. Fitzpatrick, and R. C. Murphy, “Biological activity and metabolism of 20-hydroxyeicosatetraenoic acid in the human platelet,” British Journal of Pharmacology, vol. 106, no. 2, pp. 267–274, 1992. View at Publisher · View at Google Scholar · View at Scopus
  49. N. C. Ward, J. Rivera, J. Hodgson et al., “Urinary 20-hydroxyeicosatetraenoic acid is associated with endothelial dysfunction in humans,” Circulation, vol. 110, no. 4, pp. 438–443, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. C. Fava, M. Ricci, O. Melander, and P. Minuz, “Hypertension, cardiovascular risk and polymorphisms in genes controlling the cytochrome P450 pathway of arachidonic acid: a sex-specific relation?” Prostaglandins & Other Lipid Mediators, vol. 98, no. 3-4, pp. 75–85, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. S. J. Lee, C. S. Landon, S. J. Nazian, and J. R. Dietz, “Cytochrome P-450 metabolites in endothelin-stimulated cardiac hormone secretion,” American Journal of Physiology. Regulatory, Integrative and Comparative Physiology, vol. 286, no. 5, pp. R888–R893, 2004. View at Publisher · View at Google Scholar · View at Scopus
  52. A. J. Lee, M. X. Cai, P. E. Thomas, A. H. Conney, and B. T. Zhu, “Characterization of the oxidative metabolites of 17β-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms,” Endocrinology, vol. 144, no. 8, pp. 3382–3398, 2003. View at Publisher · View at Google Scholar · View at Scopus
  53. D. L. Hertz, K. M. Kidwell, N. J. Seewald et al., “Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer,” The Pharmacogenomics Journal, vol. 17, no. 6, pp. 521–527, 2016. View at Publisher · View at Google Scholar · View at Scopus
  54. C. C. White, Q. Feng, L. A. Cupples et al., “CYP4A11 variant is associated with high-density lipoprotein cholesterol in women,” The Pharmacogenomics Journal, vol. 13, no. 1, pp. 44–51, 2013. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Yoon, “The role of PPARα in lipid metabolism and obesity: focusing on the effects of estrogen on PPARα actions,” Pharmacological Research, vol. 60, no. 3, pp. 151–159, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. J. Laganière, G. Deblois, C. Lefebvre, A. R. Bataille, F. Robert, and V. Giguère, “Location analysis of estrogen receptor α target promoters reveals that FOXA1 defines a domain of the estrogen response,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 33, pp. 11651–11656, 2005. View at Publisher · View at Google Scholar · View at Scopus